Oruka Therapeutics (NASDAQ:ORKA) Stock: Insider Joana Goncalves Sells 7,000 Shares

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $74.81, for a total transaction of $523,670.00. Following the completion of the transaction, the insider owned 31,771 shares of the company’s stock, valued at approximately $2,376,788.51. This trade represents a 18.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Joana Goncalves also recently made the following trade(s):

• On Tuesday, September 15th, Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock. The stock was sold at an average price of $92.38, for a total transaction of $734,143.86.
• On Monday, August 17th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $111.84, for a total transaction of $782,880.00.

Oruka Therapeutics Stock Performance

Shares of NASDAQ ORKA opened at $71.93 on Friday. Oruka Therapeutics, Inc. has a 52-week low of $25.11 and a 52-week high of $115.51. The firm has a 50 day moving average price of $92.45 and a two-hundred day moving average price of $80.03.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, equities analysts forecast that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current year.

Institutional Investors Weigh In On Oruka Therapeutics

A number of institutional investors have recently modified their holdings of the company. GAMMA Investing LLC lifted its holdings in Oruka Therapeutics by 201.6% in the third quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock valued at $31,000 after buying an additional 250 shares during the period. Engineers Gate Manager LP bought a new stake in Oruka Therapeutics during the second quarter valued at $350,000. Arizona State Retirement System grew its holdings in Oruka Therapeutics by 45.0% during the 2nd quarter. Arizona State Retirement System now owns 8,671 shares of the company’s stock worth $825,000 after acquiring an additional 2,691 shares during the period. Nykredit A S acquired a new stake in Oruka Therapeutics during the 2nd quarter worth about $29,000. Finally, Braidwell LP acquired a new stake in Oruka Therapeutics during the 2nd quarter worth about $26,473,000. 56.44% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Wall Street Zen downgraded Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Guggenheim reiterated a “buy” rating and issued a $200.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. HC Wainwright reissued a “buy” rating and issued a $120.00 price target on shares of Oruka Therapeutics in a research note on Thursday, September 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday. Finally, Mizuho set a $120.00 price objective on Oruka Therapeutics in a research note on Thursday, September 3rd. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Oruka Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $128.91.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company’s approach is designed to extend the duration of treatment and potentially reduce the frequency of dosing for patients with chronic inflammatory conditions.

Oruka’s pipeline includes ORKA-001 and ORKA-002, next-generation monoclonal antibodies targeting interleukin-23 (IL-23), a cytokine involved in several autoimmune and inflammatory diseases.